Celldex Therapeutics CEO and leadership

Mr. Marucci is a Founder of Celldex and serves as the Company’s President and Chief Executive Officer and as a member of the Board of Directors. Prior to his appointment as President and CEO in 2008, Mr. Marucci served as Vice President, Chief Financial Officer, Treasurer and Secretary of Celldex. Celldex, founded in 2004 as a subsidiary of Medarex (Medarex is now a wholly-owned subsidiary of Bristol Myers Squibb), was initially spun out as an independent private company in October 2005 with the asset acquisition of CDX-110 from Alteris Therapeutics, Inc. and the acquisition of Lorantis Limited (Cambridge, UK). In addition to these acquisitions, Mr. Marucci is also responsible for the AVANT Immunotherapeutics, Inc. and Celldex Therapeutics, Inc. merger completed during the first quarter of 2008 and the acquisition of CuraGen Corporation completed in the third quarter of 2009. He was Treasurer of Medarex from December 1998 to March 2004, where he held a series of senior financial positions since December 1998. He is a member of the Board of Trustees of BioNJ and also served as its Treasurer through 2010. Mr. Marucci received his B.S. in Accounting from Kean University and his M.B.A. from Columbia University.

Tibor Keler is a CSO at CELLDEX THERAPEUTICS, INC..

Specialties:Medical OncologyBoard certified medical oncologist with 30+ years of pharmaceutical industry experience, including global clinical development and medical affairs, product team leadership, and global and regional experience (especially Latin America and Canada). Responsible for the development of numerous small molecule and biologics, from Phase I through regulatory approval and reimbursement, and life cycle management (in oncology, hematology, infectious diseases, critical care, and wound healing). . Have served on the management boards of my companies/business units responsible for portfolio management. . Management for groups up to 200 professionals (physicians and clinical research scientists), and extensive experience with global matrix management. Experience in licensing and acquisition evaluations and co-development partnerships. Highly skilled in communications: excellent presentation skills, numerous external scientific and regulatory presentations (including ODAC and EMEA), media and investor relations experience. Experience as a corporate witness in product liability litigation.Very skilled in all aspects of clinical drug development including development strategy, design and execution of clinical trials, analysis of data, regulatory submissions. Also skilled in global medical affairs, including post-marketing studies, publications, scientific communications. Passionate about using my skills and knowledge to help companies bring forth new therapies that will improve the lives of patients with cancer and other unmet medical needs. In addition to my work, I enjoy serving my community. I served for 10 years on the board of the Valerie Fund, an organization dedicated to improving the care of kids with cancer and blood diseases in New Jersey. Another passion is bringing the experience of classical music to everyone. I currently serve as a Board member of the NJ Symphony Orchestra.

Richard Wright is a Senior VP/Chief Commercial Ofcr at CELLDEX THERAPEUTICS, INC.. He has worked as Managing Director at NAVIGANT CONSULTING INC and VP:Commercial Ops at CELLDEX THERAPEUTICS, INC.. Richard attended Columbia University and Rutgers University.

Elizabeth Crowley works at Bayer and a Senior VP/Chief Product Dev Ofcr at CELLDEX THERAPEUTICS, INC. and is based in Greater New York City Area. She has worked as Senior VP:Clinical Development at CELLDEX THERAPEUTICS, INC.; Senior VP:Product Development at CELLDEX THERAPEUTICS, INC.; and Director, Global Study Audit Management at Bayer Pharmaceuticals. Beth works or has worked as VP:Development Operations at CuraGen Corporation and Dir:Global Study Audit Mgmt at Bayer. She attended Boston College between 1989 and 1993.

Sam Martin is a Senior VP/CFO at CELLDEX THERAPEUTICS, INC.. He has worked as Sr Dir:Finance at CELLDEX THERAPEUTICS, INC.; Dir:Financial Reporting at CELLDEX THERAPEUTICS, INC.; and VP:Finance at CELLDEX THERAPEUTICS, INC.. Sam studied at Boston University and Skidmore, Owings & Merrill.

Mr. Marucci is a Founder of Celldex and serves as the Company’s President and Chief Executive Officer and as a member of the Board of Directors. Prior to his appointment as President and CEO in 2008, Mr. Marucci served as Vice President, Chief Financial Officer, Treasurer and Secretary of Celldex. Celldex, founded in 2004 as a subsidiary of Medarex (Medarex is now a wholly-owned subsidiary of Bristol Myers Squibb), was initially spun out as an independent private company in October 2005 with the asset acquisition of CDX-110 from Alteris Therapeutics, Inc. and the acquisition of Lorantis Limited (Cambridge, UK). In addition to these acquisitions, Mr. Marucci is also responsible for the AVANT Immunotherapeutics, Inc. and Celldex Therapeutics, Inc. merger completed during the first quarter of 2008 and the acquisition of CuraGen Corporation completed in the third quarter of 2009. He was Treasurer of Medarex from December 1998 to March 2004, where he held a series of senior financial positions since December 1998. He is a member of the Board of Trustees of BioNJ and also served as its Treasurer through 2010. Mr. Marucci received his B.S. in Accounting from Kean University and his M.B.A. from Columbia University.

Tibor Keler is a CSO at CELLDEX THERAPEUTICS, INC..

Mr. Marucci is a Founder of Celldex and serves as the Company’s President and Chief Executive Officer and as a member of the Board of Directors. Prior to his appointment as President and CEO in 2008, Mr. Marucci served as Vice President, Chief Financial Officer, Treasurer and Secretary of Celldex. Celldex, founded in 2004 as a subsidiary of Medarex (Medarex is now a wholly-owned subsidiary of Bristol Myers Squibb), was initially spun out as an independent private company in October 2005 with the asset acquisition of CDX-110 from Alteris Therapeutics, Inc. and the acquisition of Lorantis Limited (Cambridge, UK). In addition to these acquisitions, Mr. Marucci is also responsible for the AVANT Immunotherapeutics, Inc. and Celldex Therapeutics, Inc. merger completed during the first quarter of 2008 and the acquisition of CuraGen Corporation completed in the third quarter of 2009. He was Treasurer of Medarex from December 1998 to March 2004, where he held a series of senior financial positions since December 1998. He is a member of the Board of Trustees of BioNJ and also served as its Treasurer through 2010. Mr. Marucci received his B.S. in Accounting from Kean University and his M.B.A. from Columbia University.

Tibor Keler is a CSO at CELLDEX THERAPEUTICS, INC..

Richard Wright is a Senior VP/Chief Commercial Ofcr at CELLDEX THERAPEUTICS, INC.. He has worked as Managing Director at NAVIGANT CONSULTING INC and VP:Commercial Ops at CELLDEX THERAPEUTICS, INC.. Richard attended Columbia University and Rutgers University.

Dr. Pepin joined Celldex in July 2011 as Senior Vice President and Chief Business Officer. He previously served as Vice President at Shire Pharmaceuticals. From 2000 – 2009, as Senior Vice President, Business Development at Medarex, Inc., he was instrumental in establishing more than forty collaborations with global biopharmaceutical companies. Earlier in his career, he served as Executive Director of External Science and Technology at Bristol-Myers Squibb. Dr. Pepin received his B.A. from Tufts University and his Ph.D. in Genetics from Georgetown University.